Safety evaluation of desloratadine in allergic rhinitis

Bibliography

• Bousquet J, Khaltaev N, Cruz AA, Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005;28(12):1101-18
   PubMed Web of Science ®Google Scholar
• Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128:1139-50
   PubMed Web of Science ®Google Scholar
• Murdoch D, Goa KL, Keam SJ. Desloratadine. An update of its efficacy in the management of allergic disorders. Drugs 2003;63(19):2051-77
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010. J Allergy Clin Immunol 2010;126:466-7
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bindslev-Jensen C, Canonica GW, The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004;59(Suppl 77):4-16
   PubMed Web of Science ®Google Scholar
• Mullol J. Positioning of antihistamines in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. Clin Exp Allergy 2012;12:17-26
   Google Scholar
• Villa E, Rogkakou A, Garelli V, Review of desloratadine data using the ARIA Guidelines. World Allergy Organ J 2012;5(Suppl 1):S6-13
   Google Scholar
• Limon L, Kockler DR. Desloratadine: a nonsedating antihistamine. Ann Pharmacother 2003;37:237-46
   PubMed Web of Science ®Google Scholar
• Clarinex prescribing information. 2012. Available from: http://www.merck.com/product/usa/pi_circulars/c/clarinex/clarinex_pi.pdf [Last accessed 4 January 2013]
   Google Scholar
• DuBuske LM. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticarial and allergic inflammatory disorders. Expert Opin Pharmacother 2005;6(14):2511-23
   PubMed Web of Science ®Google Scholar
• Anthes JC, Gilchrest H, Richard C, Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur J Pharmacol 2002;449(3):229-37
   PubMed Web of Science ®Google Scholar
• Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751-62
   PubMed Web of Science ®Google Scholar
• Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs 2001;10:547-60
   PubMed Web of Science ®Google Scholar
• Simons FER. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17
   PubMed Web of Science ®Google Scholar
• Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001;56:7-13
   PubMed Web of Science ®Google Scholar
• Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy 2004;34:1342-8
   PubMed Web of Science ®Google Scholar
• Kreutner W, Hey JA, Anthes J, Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: 1st communication: receptor selectivity, antihistaminic activity, and anti-allergenic effects. Arzneimittelforschung 2000;50:345-52
   PubMed Web of Science ®Google Scholar
• Bachert C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 2002;57(Suppl 75):13-18
   PubMedGoogle Scholar
• Genovese A, Patella V, De Crescenzo G, Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27(5):559-67
   PubMed Web of Science ®Google Scholar
• Mullol J, Roca-Ferrer J, Alobid I, Effect of desloratadine on epithelial cell GM-CSF secretion and eosinophil survival. Clin Exp Allergy 2006;36:52-8
   PubMed Web of Science ®Google Scholar
• Mullol J, Callejas FB, Martínez-Antón A, Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respir Res 2011;12(1):23
   PubMedGoogle Scholar
• Schroeder JT, Schleimer RP, Lichtenstein LM, Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001;31:1369-77
   PubMed Web of Science ®Google Scholar
• Molet S, Gosset P, Lassalle P, Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997;27:1167-74
   PubMed Web of Science ®Google Scholar
• Kleine-Tebbe J, Josties C, Frank G, Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allergy Clin Immunol 1994;93:494-500
   PubMed Web of Science ®Google Scholar
• Letari O, Miozzo A, Folco G, Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol 1994;266(3):219-27
   PubMed Web of Science ®Google Scholar
• Greiff L, Persson CGA, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:413-18
   PubMed Web of Science ®Google Scholar
• Lippert U, Möller A, Welker P, Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000;9(2):118-24
   PubMed Web of Science ®Google Scholar
• Wang YH, Taché Y, Harris AG, Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 2005;60:117-24
   PubMed Web of Science ®Google Scholar
• Wu RL, Anthes JC, Kreutner W, Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol 2004;135:313-18
   PubMed Web of Science ®Google Scholar
• Cyr MM, Hayes LM, Crawford L, The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Int Arch Allergy Immunol 2005;138(3):209-16
   PubMed Web of Science ®Google Scholar
• Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract 2002;3:14
   PubMedGoogle Scholar
• Berger WE, Lumry WR, Meltzer EO, Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006;27:214-23
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Jalowayski AA, Vogt K, Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006;96:363-8
   PubMed Web of Science ®Google Scholar
• Day JH, Briscoe MP, Rafeiro E, Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 2004;58:109-18
   PubMed Web of Science ®Google Scholar
• Simons FER, Prenner BM, Finn A, Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003;111:617-22
   PubMed Web of Science ®Google Scholar
• Lee DKC, Gardiner M, Haggart K, Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004;34:650-3
   PubMed Web of Science ®Google Scholar
• Wilson AM, Haggart K, Sims EJ, Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:1504-9
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner UP, Zieglmayer R, Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109:956-61
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner P, Zieglmeyer R, Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003;58:481-5
   PubMed Web of Science ®Google Scholar
• Berger WE, Schenkel EJ, Mansfield LE, Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002;89:485-91
   PubMed Web of Science ®Google Scholar
• Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:1077-80
   PubMed Web of Science ®Google Scholar
• Holmberg K, Tonnel AB, Dreyfus I, Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009;64:1663-70
   PubMed Web of Science ®Google Scholar
• Kim K, Sussman G, Hébert J, Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2006;96:460-5
   PubMed Web of Science ®Google Scholar
• Canonica GW, Tarantini F, Compalati E, Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007;62:359-66
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. Allergy 2009;64:1516-23
   PubMed Web of Science ®Google Scholar
• Bachert C, van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic thinitis: a review. Clin Ther 2007;29:1795-802
   PubMed Web of Science ®Google Scholar
• Bousquet J, van Cauwenberge P, Aït Khaled N, Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy 2006;61:1086-96
   PubMed Web of Science ®Google Scholar
• Lee DKC, Bates CE, Currie GP, Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol 2003;111:337-41
   PubMed Web of Science ®Google Scholar
• Baena-Cagnani CE, Berger WE, DuBuske LM, Comparative effects of desloratadine versus montelukast on asthma symptoms and use of β2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003;130:307-13
   PubMed Web of Science ®Google Scholar
• Hoyte FCL, Katial RK. Antihistamine therapy in allergic rhinitis. Immunol Allergy Clin N Am 2011;31:509-43
   PubMed Web of Science ®Google Scholar
• Simons FER, Simons KJ. H1 antihistamines. Current status and future directions. WAO J 2008;1(9):145-55
   Google Scholar
• Salmun LM. Antihistamines in late-phase clinical development for allergic disease. Expert Opin Investig Drugs 2002;11(2):259-73
   PubMed Web of Science ®Google Scholar
• Aerius prescribing information. The European Agency for the Evaluation of Medicinal Products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002404/WC500122415.pdf [Last accessed 4 January 2013]
   Google Scholar
• Affrime M, Gupta S, Banfield C, A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002;41(Suppl 1):13-19
   PubMedGoogle Scholar
• Gupta S, Banfield C, Affrime M, Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin Pharmacokinet 2002;41(Suppl 1):1-6
   PubMedGoogle Scholar
• Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000;105:S622-7
   PubMed Web of Science ®Google Scholar
• Wilken JA, Kane RL, Ellis AK, A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:375-85
   PubMed Web of Science ®Google Scholar
• Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411
   PubMed Web of Science ®Google Scholar
• Bender BG, Berning S, Dudden R, Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003;111:770-6
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Handford ADF, Turner C, Studies on performance and sleepiness with the H1-antihistamine, desloratadine. Aviat Space Environ Med 2003;74(8):809-15
   PubMed Web of Science ®Google Scholar
• Kreutner W, Hey JA, Chiu P, Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000;50:441-8
   PubMed Web of Science ®Google Scholar
• Satish U, Streutfert S, Dewan M, Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. Allergy 2004;59:415-20
   PubMed Web of Science ®Google Scholar
• Vuurman EF, Rikken GH, Muntjewerff ND, Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004;60(5):307-13
   PubMed Web of Science ®Google Scholar
• Valk PJ, Van Roon DB, Simons RM, Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat Space Environ Med 2004;75(5):433-8
   PubMed Web of Science ®Google Scholar
• Lu HR, Hermans AN, Gallacher DJ. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? Br J Pharmacol 2012;166(4):1490-502
   PubMed Web of Science ®Google Scholar
• DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999;21(2):281-95
   PubMed Web of Science ®Google Scholar
• Banfield C, Herron J, Keung A, Desloratadine has no clinically relevant electrocardiographic or pharmacodynamics interactions with ketoconazole. Clin Pharmacokinet 2002;41(Suppl 1):37-44
   PubMedGoogle Scholar
• Bloom M, Staudinger H, Herron J. Safety of desloratadine syrup in children. Curr Med Res Opin 2004;20(12):1959-65
   PubMed Web of Science ®Google Scholar
• Salmun LM, Herron JM, Banfield C, The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clin Ther 2000;22:613-21
   PubMed Web of Science ®Google Scholar
• Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig 2010;30(2):109-22
   PubMed Web of Science ®Google Scholar
• Barbey JT, Anderson M, Ciprandi G, Cardiovascular safety of second-generation antihistamines. Am J Rhinol 1999;13:235-43
   PubMedGoogle Scholar
• Mullol J, Bousquet J, Bachert C, Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008;63(Suppl 87):5-28
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F, Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65
   PubMed Web of Science ®Google Scholar
• Bousquet J, Ansótegui I, Canonica GW, Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012;28(1):131-9
   PubMed Web of Science ®Google Scholar
• Pradalier A, Neukirch C, Dreyfus I, Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 2007;62:1331-4
   PubMed Web of Science ®Google Scholar
• Prenner B, Ballona R, Bueso A, Safety of desloratadine syrup in children six months to younger than 2 years of age: a randomized, double-blind, placebo controlled study. Pediatr Asthma Allergy Immunol 2006;19:91-9
   Google Scholar
• Phan H, Moeller ML, Nahata MC. Treatment of allergic rhinitis in infants and children. Efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs 2009;69:2541-76
   PubMed Web of Science ®Google Scholar
• Gupta SK, Kantesaria B, Banfield C, Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol 2007;64:174-84
   PubMed Web of Science ®Google Scholar
• Gupta S, Khalilieh S, Kantesaria B, Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol 2007;63:534-40
   PubMed Web of Science ®Google Scholar
• Layton D, Wilton L, Shakir SAW. Examining the tolerability of the non-sedating antihistamine desloratadine. A prescription-event monitoring study in England. Drug Saf 2009;32:169-79
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, Efficacy of desloratadine in persistent allergic rhinitis - a GA2LEN study. Int Arch Allergy Immunol 2010;153:395-402
   PubMed Web of Science ®Google Scholar
• Affrime M, Banfield C, Gupta S, Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin Pharmacokinet 2002;41(Suppl 1):21-8
   PubMedGoogle Scholar
• Prenner B, Kim K, Gupta S, Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Expert Opin Drug Saf 2006;5(2):211-23
   PubMed Web of Science ®Google Scholar
• Moretti ME, Caprara D, Couthinho CJ, Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003;111:479-83
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Salfi M, Lim JM, Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. J Clin Pharmacol 2000;50:581-9
   Web of Science ®Google Scholar
• Gupta S, Banfield C, Kantesaria B, Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-66
   PubMed Web of Science ®Google Scholar
• Banfield C, Hunt T, Reyderman L, Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002;41(Suppl 1):29-35
   PubMedGoogle Scholar
• Gupta S, Banfield C, Kantesaria B, Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol 2004;44:1252-9
   PubMed Web of Science ®Google Scholar
• Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos 2001;29(9):1173-5
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Affrime M, Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet 2002;41(Suppl 1):7-12
   PubMedGoogle Scholar
• Banfield C, Gupta S, Marino M, Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002;41(4):311-18
   PubMed Web of Science ®Google Scholar
• Church DS, Church MK. Pharmacology of antihistamines. WAO J 2011;4:S22-7
   Google Scholar
• Kalpaklioglu F, Baccioglu A. Efficacy and safety of h1-antihistamines: an update. Antiinflamm Antiallergy Agents Med Chem 2012;11(3):230-7
   PubMedGoogle Scholar
• Church MK, Maurer M, Simons FER, Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy 2010;65:459-66
   PubMed Web of Science ®Google Scholar
• Layton D, Wilton L, Boshier A, Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine. A prescription-event monitoring study in England. Drug Saf 2006;29:897-909
   PubMed Web of Science ®Google Scholar
• Bachert C, Bousquet J, Canonica GW, Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-44
   PubMed Web of Science ®Google Scholar
• Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine. A comparative review. Clin Pharmacokinet 2008;47:217-30
   PubMed Web of Science ®Google Scholar
• Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006;7:1989-2001
   PubMed Web of Science ®Google Scholar